Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.82EUR
29 Jul 2014
Price Change (% chg)

€0.49 (+0.64%)
Prev Close
€76.33
Open
€76.50
Day's High
€77.35
Day's Low
€76.36
Volume
1,690,159
Avg. Vol
2,232,606
52-wk High
€80.74
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.55
Market Cap (Mil.): €100,957.30
Shares Outstanding (Mil.): 1,322.62
Dividend: 2.80
Yield (%): 3.67

Financials

  SASY.PA Industry Sector
P/E (TTM): 26.96 35.65 36.07
EPS (TTM): 2.83 -- --
ROI: -- 18.91 18.18
ROE: -- 19.67 19.05
Search Stocks

Hungarian competition watchdog probes Sanofi subsidiary

BUDAPEST/PARIS - Hungary's competition watchdog GVH has raided the Hungarian headquarters of French drug maker Sanofi as the first step of proceedings against the firm for suspected abuse of its dominant market position.

12:14am IST

UPDATE 1-Hungarian competition watchdog probes Sanofi subsidiary

BUDAPEST/PARIS, July 29 - Hungary's competition watchdog GVH has raided the Hungarian headquarters of French drug maker Sanofi as the first step of proceedings against the firm for suspected abuse of its dominant market position.

12:06am IST

Hungary launches probe against Sanofi-Aventis

BUDAPEST, July 29 - Hungary's competition watchdog GVH has raided the Hungarian headquarters of French drug maker Sanofi-Aventis as the first step of a proceedings against the firm for a suspected abuse of its dominant market position, GVH said on Tuesday.

29 Jul 2014

IATA seeks meeting with Venezuela president over money owed to airlines

BERLIN, July 28 - A leading air transport industry body has called for a top-level meeting with the Venezuelan president to discuss ways to restore over $4 billion of airlines' money that is trapped in the country due to its currency controls.

28 Jul 2014

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

16 Jul 2014

India caps price of 108 more medicines; drugmakers to take hit

MUMBAI - India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

UPDATE 1-India caps price of 108 more medicines; drugmakers to take hit

* Move aimed towards making drugs more affordable in India

14 Jul 2014

India caps prices of 108 more medicines; drugmakers to take hit

MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease. | Video

11 Jul 2014

Earnings vs. Estimates

Search Stocks